Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state

Thrombosis Research

Volumn 82, Issue 3, 1996, Pages 235-244

  Sakata, Toshiyuki ^a   Kario, Kazuomi ^a   Katayama, Yoshiaki ^a   Matsuyama, Tatsuo ^a   Kato, Hisao ^a   Miyata, Toshiyuki ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Activated factor VII; APC resistance; Hypercoagulable state; Normalized APC sensitivity ratio; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 7;

ACTIVATED PROTEIN C RESISTANCE; ARTICLE; ASSAY; CONTROLLED STUDY; HUMAN; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THROMBOSIS;

EID: 0029952373     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(96)00070-9     Document Type: Article

References (29)

1. DAHLBÄCK B., CARLSSON M. and SVENSSON P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90, 1004-8, 1993.
2. SVENSSON P.J. and DAHLBÄCK B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330, 517-22, 1994.
3. KOSTER T., ROSENDAAL F.R., DE RONDE H., BRIET E. VANDENBROUKE J.P. and BERTINA R.M. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342, 1503-6, 1993.
4. GRIFFIN J.H., EVATT B., WIDEMAN C. and FERNANDEZ J.A. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82, 1989-93, 1993.
5. DAHLBÄCK B. and HILDEBRAND B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factors V. Proc Natl Acad Sci USA 21, 1396-400, 1994.
6. BERTINA R.M., KOELEMAN B.P.C., KOSTER T., ROSENDAAL F.R., DIRVEN R.J., DE RONDE H., VAN DER VELDEN P.A. and REISTMA P.H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369, 64-7, 1994.
7. GREENGARD J.S., SUN X., XU X., FERNANDEZ J.A., GRIFFIN J.H. and EVATT B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 343, 1361-2, 1994.
8. ZÖLLER B. and DAHLBÄCK B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343, 1536-8, 1994.
9. HALBMAYER W.M., HAUSHOFER A., SCHÖN R. and FISCHER M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis 5, 51-7, 1994.
10. FORSYTH P.D. and GOLAN G. Activated protein C resistance in cases of cerebral infarction. Lancet 345, 795, 1995.
11. LINDBLAD B, SVENSSON P.J. and DAHLBÄCK B. Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C. Lancet 343, 917, 1994.
12. KONTULA K., YLIKORKALA A., MIETTINEN H., VUORIO A., KAUPPINEN M., HÄMLÄINEN L., PALOMAKI H. and KASTE M. Arg506Gln factor V mutation (Factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 73, 558-60, 1995.
13. RIDKER P.M., HENNEKENS C.H., LINDPAINTNER K., STAMPFER M.J., EISENBERG P.R. and MILETICH J.P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332. 912-7, 1995.
14. RAPAPORT S.I., and RAO L.V.M. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 12, 1111-21, 1992.
15. WILCOX J.N., SMITH K.M., SCHWARTZ S.M. and GORDON D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86, 2839-43, 1989.
16. MORRISSEY J.H., MACIK B.G., NEUENSCHWANDER P.F. and COMP P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81, 734-44, 1993.
17. KARIO K., MIYATA T., SAKATA T., MATSUO T. and KATO H. Fluorogenic assay of activated factor VII: Plasma factor Vila levels in relation to arterial cardiovascular disease in Japanese. Arterioscler Thromb 14, 265-74, 1994.
18. KARIO K., SAKATA T., MATSUO T., and MIYATA T. Factor VII in non-insulin-dependent diabetic patients with microalbuminuria. Lancet 342, 1552, 1993.
19. FUJIMURA H., KAMBAYASHI J., MONDEN M., KATO H., and MIYATA T. Coagulation factor V Leiden mutation may have a racial background. Thromb Haemost 74, 1381-2, 1995.
20. WHITSNAT J.P., BASFORD J.R., BERNSTEIN E.F., COOPER E.S., DYKEN M.L., EASTON J.D., LITTLE J.R., MARLER J.R., MIILLIKEN C.H., PETITO C.K., PRICE T.R., RAICHLE M.E., ROBERTSON J.T., THIELE B., WALKER M.D. and ZIMMERMAN R.A. A committee established by the Director of the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. Stroke 21, 637-76, 1990.
21. DE RONDE H. and BERTINA R.M. Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 72, 880-6, 1994.
22. MIYATA T., ZHENG Y.Z., SAKATA T., TSUSHIMA N. and KATO H. Three missense mutations in the protein C heavy chain causing type I and type II protein C deficiency. Thromb Haemost 71, 32-7, 1994.
23. BAUER K.A. and ROSENBERG R.D. The pathophysiology of the prethrombotic state in humans. Blood 70, 343-50, 1987.
24. BOUEU B., BES G., PELZER H., SIE P. and BOCCALON H. D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: Diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 65, 28-32, 1991.
25. KARIO K., MATSUO T., SAKATA T. and MIYATA T. Factor VII hyperactivity and ischaemic heart disease. Lancet 343, 233, 1994.
26. KARIO K., MATSUO M., KOIDE M., YAMADA T., NAKAMURA S., SAKATA T., KATO H. and MIYATA T. Marked increase of activated factor VII in uremic patients. Thromb Haemost 72, 763-7, 1995.
27. VANDENBROUCKE J.P., KOSTER T., BRIET E., REITSMA P.H. and BERTINA R.M. and ROSENDAAL F.R. Increased risk of venous thrombosis in a oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344, 1453-7, 1994.
28. HENKENS C.M.A., BOM V.J.J., SEINEN A.J. and VAN DER MEER J. Sensitivity to activated protein C; Influence of oral contraceptives and sex. Thromb Haemost 73, 402-4, 1995.
29. HALBMAYER W.M., HAUSHOFER A., SCHON R. and FISCHER M. Influence of lupus anticoagulant on a commercially available kit for APC-resistance. Thromb Haemost 72, 645-6, 1994.